Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework
- PMID: 19686541
- DOI: 10.1111/j.1742-7843.2009.00456.x
Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework
Abstract
The aim of this conceptual framework paper is to contribute to the further development of the modelling of effects of drugs or toxic agents by an approach which is based on the underlying physiology and pathology of the biological processes. In general, modelling of data has the purpose (1) to describe experimental data, (2a) to reduce the amount of data resulting from an experiment, e.g. a clinical trial and (2b) to obtain the most relevant parameters, (3) to test hypotheses and (4) to make predictions within the boundaries of experimental conditions, e.g. range of doses tested (interpolation) and out of the boundaries of the experimental conditions, e.g. to extrapolate from animal data to the situation in man. Describing the drug/xenobiotic-target interaction and the chain of biological events following the interaction is the first step to build a biologically based model. This is an approach to represent the underlying biological mechanisms in qualitative and also quantitative terms, thus being inherently connected in many aspects to systems biology. As the systems biology models may contain variables in the order of hundreds connected with differential equations, it is obvious that it is in most cases not possible to assign values to the variables resulting from experimental data. Reduction techniques may be used to create a manageable model which, however, captures the biologically meaningful events in qualitative and quantitative terms. Until now, some success has been obtained by applying empirical pharmacokinetic/pharmacodynamic models which describe direct and indirect relationships between the xenobiotic molecule and the effect, including tolerance. Some of the models may have physiological components built in the structure of the model and use parameter estimates from published data. In recent years, some progress toward semi-mechanistic models has been made, examples being chemotherapy-induced myelosuppression and glucose-endogenous insulin-antidiabetic drug interactions. We see a way forward by employing approaches to bridge the gap between systems biology and physiologically based kinetic and dynamic models. To be useful for decision making, the 'bridging' model should have a well founded mechanistic basis, but being reduced to the extent that its parameters can be deduced from experimental data, however capturing the biological/clinical essential details so that meaningful predictions and extrapolations can be made.
Similar articles
-
Proper lumping in systems biology models.IET Syst Biol. 2009 Jan;3(1):40-51. doi: 10.1049/iet-syb:20070055. IET Syst Biol. 2009. PMID: 19154083
-
Physiologically based pharmacokinetics (PBPK).Drug Metab Rev. 2009;41(3):391-407. doi: 10.1080/10837450902891360. Drug Metab Rev. 2009. PMID: 19601719 Review.
-
Quantitative structure-pharmacokinetic/pharmacodynamic relationships.Adv Drug Deliv Rev. 2006 Nov 30;58(12-13):1326-56. doi: 10.1016/j.addr.2006.08.002. Epub 2006 Sep 19. Adv Drug Deliv Rev. 2006. PMID: 17092600 Review.
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
-
SysBioMed report: advancing systems biology for medical applications.IET Syst Biol. 2009 May;3(3):131-6. doi: 10.1049/iet-syb.2009.0005. IET Syst Biol. 2009. PMID: 19449974
Cited by
-
Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians.Paediatr Drugs. 2024 Jul;26(4):365-379. doi: 10.1007/s40272-024-00633-x. Epub 2024 May 16. Paediatr Drugs. 2024. PMID: 38755515 Review.
-
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.Invest New Drugs. 2020 Dec;38(6):1796-1806. doi: 10.1007/s10637-020-00953-y. Epub 2020 May 25. Invest New Drugs. 2020. PMID: 32451663
-
Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.Clin Pharmacokinet. 2020 Feb;59(2):123-135. doi: 10.1007/s40262-019-00828-3. Clin Pharmacokinet. 2020. PMID: 31654368 Review.
-
Physiological fidelity or model parsimony? The relative performance of reverse-toxicokinetic modeling approaches.BMC Syst Biol. 2017 Mar 11;11(1):35. doi: 10.1186/s12918-017-0407-3. BMC Syst Biol. 2017. PMID: 28284215 Free PMC article.
-
Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.Clin Neuroradiol. 2017 Jun;27(2):199-203. doi: 10.1007/s00062-015-0464-1. Epub 2015 Sep 8. Clin Neuroradiol. 2017. PMID: 26350588
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous